CAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the ...

For the fourth time in five months, the Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

Moderna has lowered 2025 revenue guidance after a tough 2024 coronavirus vaccination season. However, the company aims to launch 10 new products over the next few years -- and that could lead to ...

Moderna's share price plunged after the company cut its 2025 sales guidance. The mRNA pioneer sees considerable uncertainty in the vaccine market. However, Moderna still expects 10 product ...

There have been 67 confirmed human bird flu cases in the U.S. since April 2024. Moderna has been awarded approximately $590 million from the federal government to help speed up the development of ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two ...